Who Paid My Doc
Patrick Rask
Interventional Pain Medicine Corvallis, OR Medical Doctor
NPI 1427188309 CMS profile 291191
800 Ne Circle Blvd, Corvallis, OR 97330
General payments
$6,990
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Patrick Rask of Corvallis, OR is reported in the CMS Open Payments database as having received $6,990 across 198 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 65th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $276 | 9 | |
| 2024 | General | $507 | 10 | |
| 2023 | General | $1,256 | 19 | |
| 2022 | General | $1,850 | 19 | |
| 2021 | General | $1,011 | 56 | |
| 2020 | General | $689 | 44 | |
| 2019 | General | $1,400 | 41 |
Beside peers
- Patrick Rask
- Interventional Pain Medicine median
- Middle half of Interventional Pain Medicine
- National median
In program year 2025, general payments to Patrick Rask were reported at $276. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.
Show as a table
| Year | Patrick Rask | Interventional Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,400 | $684 | $216–$2,079 | $163 |
| 2020 | $689 | $382 | $122–$1,109 | $114 |
| 2021 | $1,011 | $552 | $167–$1,554 | $132 |
| 2022 | $1,850 | $605 | $187–$1,924 | $149 |
| 2023 | $1,256 | $671 | $195–$1,915 | $160 |
| 2024 | $507 | $684 | $206–$1,837 | $164 |
| 2025 | $276 | $657 | $184–$1,753 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 16 drugsPart D claims
674
Drug cost
$5,337
Branded share of claims
6.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Pregabalin | Generic | 42 | $876 | |
| Celecoxib | Generic | 81 | $789 | |
| Gabapentin | Generic | 67 | $740 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 43 | $668 | |
| Baclofen | Generic | 38 | $415 | |
| Oxycodone Hcl | Generic | 37 | $343 | |
| Tizanidine Hcl | Generic | 50 | $312 | |
| Methocarbamol | Generic | 14 | $225 | |
| Duloxetine Hcl | Generic | 18 | $200 | |
| Doxepin Hcl | Generic | 13 | $178 |
The 10 drugs with the highest cost, of 16 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 60 billing codesPaid by Medicare
$192,780
Medicare patients
606
Services billed
10,808
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 69% | |
| Depression | 31% | |
| Diabetes | 26% | |
| Chronic kidney disease | 20% | |
| Ischemic heart disease | 18% | |
| COPD | 16% | |
| Atrial fibrillation | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, onabotulinumtoxina, 1 unit J0585 | Office | 27 | 6,300 | $30,859 |
| Injection, incobotulinumtoxin a, 1 unit J0588 | Office | 11 | 1,100 | $4,263 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 53 | 169 | $121 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 50 | 399 | $34 |
| Injection, methylprednisolone sodium succinate, up to 40 mg J2920 | Office | 12 | 12 | $33 |
| Injection, methylprednisolone sodium succinate, 5 mg J2919 | Office | 13 | 25 | $6 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
198 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Pain Medicine in Oregon
Gregory Moore
Interventional Pain Medicine · Eugene, OR
Gregory Phillips
Interventional Pain Medicine · Eugene, OR
Stephen Peirce
Interventional Pain Medicine · Eugene, OR
Rishi Vora
Interventional Pain Medicine · Eugene, OR
George Johnston
Interventional Pain Medicine · Medford, OR
Poly Chen
Interventional Pain Medicine · Salem, OR
Related records
Interventional Pain Medicine in Oregon
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Oregon
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.